CVS Agrees to $315 Million Settlement Over Alleged Illegal Opioid Prescriptions
CVS pays $315 million to settle federal claims over illegal opioid dispensing and Controlled Substances Act violations from 2013 to 2025.
Stocks · News reference
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts review high-yield healthcare stocks CVS, Medtronic and GSK, offering dividend yields of 3.02%-3.86% and varied ratings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
QUICK SPARK: UnitedHealth Calls 2026 the Bottom for Medicaid Margins
UnitedHealth expects Medicaid margins to bottom in 2026 and improve through 2028, UnitedHealthcare CEO Tim Noel says on earnings call.
CVS Agrees To Pay $315M For Illegally Filling Unlawful Opioid Prescriptions And For Submitting False Claims To The Federal Government
https://www.justice.gov/opa/pr/cvs-agrees-pay-315m-illegally-filling-unlawful-opioid-prescriptions-and-submitting-false
'CVS agrees to pay $315 million to settle Justice Department case over opioid prescriptions' - Associated Press
Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire?
D-Wave Quantum has surged over 1,000% in two years, but the article cautions that much of this rally is driven by hype rather than operational results. While the company shows strong booking growth (1,120% YoY), revenue remains flat at $3.1M and operating losses doubled to $53.3M. With a P/S ratio of 362, the stock is priced for perfection, and analysts suggest waiting for a lower entry point despite the transformational potential of quantum computing technology.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.